Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Cipher Pharmaceuticals Inc. (T:CPH)

Business Focus: Pharmaceuticals

INK Edge Outlook

Mostly sunny as of October 01, 2021
For the latest outlook, get the company report

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for CPH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Sep 08, 2021 07:30 ET
Cipher Pharmaceuticals Announces Renewal of Normal Course Issuer Bid
OAKVILLE, ON, Sept. 8, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to renew its normal course issuer bid ("NCIB") for its common shares (the "Common Shares"). 
Read full article
Aug 12, 2021 17:00 ET
Cipher Reports 30% Revenue Growth and 40% Adjusted EBITDA Growth in Second Quarter of 2021, Driven by Strength in Epuris and Absorica
Revenue increases 30% to $6.1 million, Adjusted EBITDA2 increases 40% to $4.1 million EPS increases 450% to $0.11 (CDN$0.141) Epuris revenue grows 63%, Absorica revenue grows 25% All figures in U.S. dollars, unless otherwise noted OAKVILLE, ON, Aug. 12, 2021 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced its financial and operating results for the three and six-months ended June 30, 2021. Unless otherwise noted, all figures are in U.S. dollars.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.40
--
--
Price to Sales - TTM
2.56
16.96
12.80
Price to Book - most recent quarter
1.57
3.79
3.24
Price to Cash Flow per share - TTM
8.69
13.20
13.34
Price to Free Cash Flow per share - TTM
4.83
15.78
32.58
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Oct 15, 20213,022-7,127
Sep 30, 202110,149-137,826
Sep 15, 2021147,975141,954
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol. Its pipeline of late-stage products includes DERMADEXIN, BETEFLAM PATCH, SITAVIG, PRURIDEXIN, OZENOXACIN, CF101 for plaque psoriasis, CF101 for rheumatoid arthritis, ASF-1096 and NANOLIPOLEE-007. It operates in Canada and the United States.

See business summary

 

Twitter

Search (past week) for $CPH.CA

  • No tweets found